Read clinically focused news coverage of key developments from the meeting. Medscape Ophthalmology
Category: News
Ranibizumab Outcomes at 2 Years: Are They Holding Up?
The 2-year follow-up results are in for intravitreal ranibizumab in the treatment of diabetic macular edema. Medscape Ophthalmology
Femtosecond Laser Increases Astigmatic Keratotomy Accuracy
Femtosecond laser makes astigmatic keratotomy more accurate and offers surgeons greater flexibility. Medscape Medical News
WSU’s novel gene-therapy for blindness receives $250,000 FFB grant
Technology to restore vision through the use of a component of green algae – developed by a Wayne State University professor and scientific director of the Ligon Research Center of Vision at the Kresge Eye Institute – has attracted additional funding f…
Intraocular Ranibizumab No Quick Fix for Macular Edema
Up to two years of intraocular ranibizumab injections (Lucentis, Genetech) are safe in patients with retinal vein occlusion, researchers say. Reuters Health Information
Omega-3 Slows Down Retinitis Pigmentosa Progression
A report published Online First by Archives of Ophthalmology, one of the JAMA/Archives journals, reveals that adults with retinitis pigmentosa who took vitamin A supplements over a period of four to six years, showed slower decline in annual rates of …
Prostaglandin Analogs And Laser Trabeculoplasty Prove Cost Effective For Treating Glaucoma
A study published Online First by Archives of Ophthalmology, reveals that glaucoma medication known as prostaglandin analogs (PGAs) and laser trabeculoplasty (LTP), a small invasive procedure both seem cost-effective options for patients with newly di…
Getting Better Informed Consent Before Surgery
Is one method of preparing patients for informed consent for cataract surgery better than another? Medscape Ophthalmology
New Operation For Complex Strabismus Or Cross Eyes Offers Faster Recovery, More Precise Results
People with strabismus (misalignment and limited movement of one or more eyes) are often teased about their crossed-eye appearance; those with more complex, disfiguring strabismus can become socially isolated and develop neck and back problems from hav…
Aganirsen demonstrates significant activity in two models of wet AMD, ischemic retinopathy
Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, today announced the publication of data demonstrating the significant activity of aganirsen (GS-101, eye drops) in two important models of retinal ne…
Intraoperative and Postoperative Complications of LASIK
LASIK is one of the most widely performed ophthalmic procedures. Technologic advances have made it safer, but complications do occur. How is it best to manage them, and can they be avoided? Expert Review of Ophthalmology
Adding Omega-3s May Help Slow Vision Loss (CME/CE)
(MedPage Today) — The combination of vitamin A supplementation and a diet high in omega-3 fatty acids may slow the loss of visual acuity for patients with retinitis pigmentosa, researchers found.
New Glaucoma Drug Zioptan Wins FDA Approval
On Friday, the US Food and Drug Administration approved Merck’s Zioptan, a once-daily preservative-free opthalmic solution of tafluprost, a prostaglandin analog for lowering high intra-ocular pressure in patients with open-angle glaucoma or with high…
Technology Lends Product Packaging A Voice To Aid Visually And Hearing Impaired
As the proportion of senior citizens grows, their special needs are gaining momentum. Human eyesight, for example, weakens with age. VTT Technical Research Centre of Finland has been developing new NFC-based applications that make life easier for the v…
Choose Glaucoma Treatment Based on Risk of Poor Adherence
A new study has found that laser trabeculoplasty and prostaglandin analogs are cost-effective options in managing glaucoma, but trabeculoplasty may be better in patients at risk for poor adherence. Medscape Medical News
New Glaucoma Drug Approved
(MedPage Today) — The FDA has approved an ophthalmic solution of tafluprost (Zioptan), a prostaglandin analog, for patients with open-angle glaucoma, its manufacturer said Monday.
Third patient dosed in Phase 1/2 SMD trial using RPE cells derived from hESCs
Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today the dosing of third patient in its Phase 1/2 trial for Stargardt’s macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human e…
Merck’s ZIOPTAN for reducing elevated IOP receives FDA approval
Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration has approved ZIOPTANTM (tafluprost ophthalmic solution) 0.0015%, the first preservative-free prostaglandin analog ophthalmic solution.
Regeneron reports total revenues of $123.0M for fourth quarter 2011
Regeneron Pharmaceuticals, Inc. today announced financial and operating results for the fourth quarter and full year 2011 and provided an update on development programs.
A New Tool in the MS Clinic?
Medscape sits down with Jack N. Ratchford, MD, to discuss potential applications of optical coherence tomography in multiple sclerosis. Medscape Neurology